Consensus and clinical recommendations for nutritional intervention for head and neck cancer patients undergoing chemoradiotherapy in Taiwan
Head and neck cancer (HNC) is one of the most common malignancies worldwide [1]. In patients with advanced HNC, the standard of care often involves radical resection, chemotherapy, and radiotherapy [2]. Multidisciplinary treatments invariably cause mucositis, xerostomia, and odynophagia, resulting in swallowing disabilities. In addition, severe malnourishment may interrupt treatment or even cause death. Poor nutritional status increases radiation-induced toxicity and is associated with poor clinical outcome [3]. (Source: Oral Oncology)
Source: Oral Oncology - April 11, 2018 Category: Cancer & Oncology Authors: Mei-Chun Lin, Pei-Wei Shueng, Wei-Kuo Chang, Peter Mu-Hsin Chang, Hsin-Chun Feng, Muh-Hwa Yang, Pei-Jen Lou Tags: Review Source Type: research
Factors associated with increased risk of suicide among survivors of head and neck cancer: A population-based analysis
More than 15 million individuals in the United States are currently living with a cancer diagnosis [1], 430,000 of whom are head and neck cancer (HNC) survivors [2]. The number of HNC survivors is projected to increase mostly due to decreasing smoking rates, decreasing smoking related head and neck cancer, and increasing incidence of human papillomavirus (HPV)-related head and neck cancer [2]. Post-diagnosis, survivors face survival and lifestyle-related comorbidities and competing causes of death, including depression and suicide [3 –5]. (Source: Oral Oncology)
Source: Oral Oncology - April 11, 2018 Category: Cancer & Oncology Authors: Nosayaba Osazuwa-Peters, Lauren D. Arnold, Travis M. Loux, Mark A. Varvares, Mario Schootman Source Type: research
Report of a consensus meeting of a group of oral and general pathologists in India on grading of oral epithelial dysplasia
Sixteen Indian pathologists who expressed an interest on enrolling at a satellite workshop to the 6th Congress of the International Academy of Oral Oncology (IAOO) were invited to discuss practical implications on reporting of oral epithelial dysplasia (OED). Fourteen attended representing different pathology centres in India, with good regional and national representation; 09 were oral pathologists and 05 were general pathologists. The proceedings and the groups ’ consensus are reported here. (Source: Oral Oncology)
Source: Oral Oncology - April 11, 2018 Category: Cancer & Oncology Authors: Saman Warnakulasuriya, W.M. Tilakaratne, K. Ranganathan, Moni A. Kuriakose Tags: Letter to the editor Source Type: research
A Nomogram based prognostic score that is superior to conventional TNM staging in predicting outcome of surgically treated T4 buccal mucosa cancer: Time to think beyond TNM
TNM staging system since 1953, when it was first proposed by French surgeon, Denoix [1,2], to Union for International Cancer Control (UICC) for staging and prognostication of solid tumors, has fulfilled its original mandate remarkably. Initially, based on the simple theory that outcomes worsened as the tumor progressed from the primary site (T) to regional lymph nodes (N) and then to distant organs (M), TNM system has evolved over the years [2]. The American joint committee on cancer (AJCC) and UICC versions of the TNM system were unified in 1987 and since then through continuous collaboration these organizations have main...
Source: Oral Oncology - April 10, 2018 Category: Cancer & Oncology Authors: Saurabh Bobdey, Manish Mair, Sudhir Nair, Deepa Nair, Ganesh Balasubramaniam, Pankaj Chaturvedi Source Type: research
Integrated genomic characterization of oral carcinomas in post-hematopoietic stem cell transplantation survivors
Successes in hematopoietic stem cell transplantation (HSCT) over the last few decades to cure many patients of their underlying hematologic malignancies has resulted in a surge of patients followed long-term. To that end, it has become increasingly recognized that the risk of secondary cancers in survivors of allogeneic HSCT is high [1]. The most frequent secondary cancer is squamous cell carcinoma (SCC) of the oral cavity, representing a 16-fold higher risk among HSCT patients compared with the general population [2]. (Source: Oral Oncology)
Source: Oral Oncology - April 10, 2018 Category: Cancer & Oncology Authors: Glenn J. Hanna, Eric R. Kofman, Muhammad Ali Shazib, Sook-bin Woo, Brendan Reardon, Nathaniel S. Treister, Robert I. Haddad, Corey S. Cutler, Joseph H. Antin, Eliezer M. Van Allen, Ravindra Uppaluri, Robert J. Soiffer Source Type: research
Microsatellite instability associated with durable complete response to PD-L1 inhibitor in head and neck squamous cell carcinoma
Survival of recurrent or metastatic Head and Neck Squamous Cell Carcinoma patients (R/M-HNSCC) is still short. The median survival time of patients treated by platinum-based chemotherapy plus cetuximab is 10.1 months [1]. Recently, nivolumab, a PD-1 inhibitor, demonstrated a gain in overall survival in pretreated R/M-HNSCC in comparison to standard treatment [2]. Other checkpoint inhibitors targeting PD-1 (pembrolizumab) or PD-L1 (atezolizumab, durvalumab) also showed activity with objective response r ates ranging between 13 and 18% [3–5]. (Source: Oral Oncology)
Source: Oral Oncology - April 6, 2018 Category: Cancer & Oncology Authors: Magalie P. Tardy, Ilaria Di Mauro, Nathalie Ebran, Sadal Refae, Alexandre Bozec, Karen Benezery, Fr édéric Peyrade, Joel Guigay, Anne Sudaka-Bahadoran, Cécile Badoual, Florence Pedeutour, Esma Saada-Bouzid Tags: Letter to the editor Source Type: research
Utility of PET-CT in detecting nodal metastasis in cN0 early stage oral cavity squamous cell carcinoma
Oral cavity squamous cell carcinoma (OCSCC) is a devastating disease that has significant impacts on function and quality of life. Nodal status is one of the most important prognostic factors and significantly impacts treatment options [1]. The presence of nodal metastasis decreases survival by up to 50% [2]. The rates of occult metastasis in OCSCC are high with an estimated range of 14 –45% [4–8]. Rates are known to be higher for certain sub-sites, large-volume tumors (e.g. T3 and T4), and tumors with adverse features, such as perineural invasion and depth of invasion [9–12]. (Source: Oral Oncology)
Source: Oral Oncology - April 5, 2018 Category: Cancer & Oncology Authors: Han Zhang, Hadi Seikaly, Vincent L. Biron, Caroline C. Jeffery Source Type: research
Hypoxia modulates CCR7 expression in head and neck cancers
Tumours occurring in the anatomical regions of the head and neck are the sixth most common types of cancer worldwide, with over 500,000 new cases and over 350,000 deaths reported every year [1]. A particularly unwelcome hallmark of head and neck cancers is the high incidence of metastasis, particularly to regional lymph nodes. In fact, by the time of diagnosis, nearly half of head and neck cancers have already metastasised to neck lymph nodes and one in ten has metastasised to distant organs [2]. (Source: Oral Oncology)
Source: Oral Oncology - April 4, 2018 Category: Cancer & Oncology Authors: Haneen A. Basheer, Edvinas Pakanavicius, Patricia A. Cooper, Steven D. Shnyder, Lisette Martin, Keith D. Hunter, Victoria Vinader, Kamyar Afarinkia Source Type: research
Risk factors for salivary gland cancers in France: Results from a case-control study, the ICARE study
The major salivary glands occur in three pairs (the parotid, submandibular, and the sublingual glands), while the minor salivary glands occur as several hundred structures scattered within the mucous membranes of the mouth, oropharynx, larynx, nose, and the paranasal sinuses. In France, the cancers of the major salivary glands are rare, with an estimated incidence of 0.7/100,000 person-years in men and 0.5/100,000 person-years in women [1], and account for 1.9% and 8.6% of head and neck cancers (HNC) in men and in women, respectively [2]. (Source: Oral Oncology)
Source: Oral Oncology - April 4, 2018 Category: Cancer & Oncology Authors: Loredana Rado ï, Christine Barul, Gwenn Menvielle, Matthieu Carton, Mireille Matrat, Marie Sanchez, Corinne Pilorget, Michel Velten, Isabelle Stücker, Danièle Luce, ICARE Study Group Source Type: research
Multi-criteria optimization achieves superior normal tissue sparing in intensity-modulated radiation therapy for oropharyngeal cancer patients
Combined concomitant chemoradiotherapy is the standard treatment for non-resectable patients with oropharyngeal cancer (OPC), and is also preferable for resectable patients whose anticipated functional outcome with surgical treatment is poor [1]. Particularly, OPC with human papilloma viruses more sensitive to radiotherapy and chemotherapy [2 –4]. Studies demonstrated that intensity-modulated radiation therapy (IMRT) is associated with better locoregional control, survival rates, quality of life and less complication of radiotherapy for OPC [5–12]. (Source: Oral Oncology)
Source: Oral Oncology - April 4, 2018 Category: Cancer & Oncology Authors: Jianghong Xiao, Yan Li, Huashan Shi, Tangel Chang, Yong Luo, Xuetao Wang, Yang He, Nianyong Chen Source Type: research
A predictive model for recurrence in patients with glottic cancer implemented in a mobile application for Android
Cancer of the larynx is one of the most frequent cancers of the head and neck [1 –3]. Its incidence adjusted for age is estimated in the United States at 5.4 cases per 100,000 inhabitants in men and 1.1 cases per 100,000 inhabitants in women [4]. These figures are slightly higher in men in Europe, where there are 8.8 incident cases per 100,000 inhabitants, while in women the f igure is slightly lower, at 0.8 cases per 100,000 inhabitants [5,6]. Survival at five years is approximately 60% in both the United States and Europe [4,7]. (Source: Oral Oncology)
Source: Oral Oncology - April 4, 2018 Category: Cancer & Oncology Authors: Ana Gabriela Jover-Espl á, Antonio Palazón-Bru, David Manuel Folgado-de la Rosa, Guillermo Severá-Ferrándiz, Manuela Sancho-Mestre, Joaquín de Juan-Herrero, Vicente Francisco Gil-Guillén Source Type: research
Editorial Board/Aims & Scope
(Source: Oral Oncology)
Source: Oral Oncology - April 1, 2018 Category: Cancer & Oncology Source Type: research
Patients with integrated HPV16 in head and neck cancer show poor survival
Human papillomavirus (HPV) and in particular HPV16 is a causative agent in a variety of cancers that include cervical cancer, ano-genital cancers, and head and neck cancers. The incidence of HPV-mediated head and neck cancer (HNC), has been on the rise in the US, in contrast to the reduction of non-HPV HNC that parallels reduction in tobacco use [1]. HPV16 is an 8 Kb DNA virus that is found in one of two physical states in cancer cells, episomal or integrated. The episomal HPV genome is a circular autonomously replicated DNA structure. (Source: Oral Oncology)
Source: Oral Oncology - March 29, 2018 Category: Cancer & Oncology Authors: Tara J. Nulton, Nak-Kyeong Kim, Laurence J. DiNardo, Iain M. Morgan, Brad Windle Source Type: research
